International medical journal reports Vancouver product`s

CNW Telbec | FARABLOC DEVELOPMENT CORPORATION | Internat...
1 von 2
http://www.cnw.ca/fr/releases/archive/January2007/23/c8275.html
ACCUEIL / ENGLISH / CARTE DU SITE / À PROPOS DE CNW TELBEC / POUR COMMUNIQUER AVEC NOUS / PRODUITS ET
SERVICES / OUVERTURE DE SESSION ACCÈS CNW / PORTABLE
5 février 2009
SUJETS
D'ACTUALITÉ
Résultats financiers
Ventes Automobiles
Budget Fédéral
2009
NOUVELLES ET
RENSEIGNEMENTS
:
Communiqués de
presse
Webdiffusions /
Baladodiffusions
Photos
Diffusion sur
demande
Communiqué Médias sociaux
Au fil de la journée
des médias
Banque de données
des résultats
financiers
Envoyez un
communiqué
Nouvelles XBRL
Widget CNW
Les façons d’obtenir
des Nouvelles de
CNW
SERVICES
GRATUITS
INSCRIPTION:
Sentinelle CNW
Alimentation RSS
Calendrier de
diffusion sur le Web
Viigo
OUTILS POUR :
Médias
Investisseurs
RESSOURCES :
Événements CNW
Partenaires
Répertoire des
bourses
RECHERCHE RAPIDE PAR ORGANISME
ALLEZ
AUTRES OPTIONS DE
RECHERCHE
>DITES-LE À UN AMI >VERSION IMPRIMABLE >ABONNEZ-VOUS À SENTINELLE CNW
Attention News/Health Editors:
International medical journal reports Vancouver product's success in easing
fibromyalgia pain
VANCOUVER, Jan. 23 /CNW/ - A distinguished British medical journal,
Clinical Rheumatology, has just published an article concerning the remarkable
pain-reduction results of Farabloc, developed and manufactured by a
Vancouver-headquartered company, in studies of patients suffering from
fibromyalgia.
Fibromyalgia is a chronic condition characterized by fatigue and
widespread pain in muscles, ligaments and tendons, creating multiple tender
points. This rheumatic condition creates chronic pain at these tender points
disturbing most normal activities. There is a predominance of women among
those afflicted with the disease. Symptoms vary among patients from mild to
severe but cures have been virtually non-existent. Debilitating side effects
complicate many therapies based on chronic drug use.
The research report, The Efficacy of Farabloc, as an Analgesic in Primary
Fibromyalgia, was authored by Dr. Gerhard L. Bach of Germany, who collected
the clinical data, and Dr. Douglas B. Clement, Professor Emeritus, Division of
Sports Medicine at the University of British Columbia, who compiled and
analyzed the data. Professor Bach who has an academic affiliation with the
Department of Medicine/Rheumatology at the University of Munich, conducted the
research at Clinic Auerbach, Bensheim.
Farabloc, an electromagnetic shielding fabric, contains extremely fine
stainless steel fibres and nylon, with an appearance similar to linen. This
drug-free product has a significant shielding effect on high frequency
electromagnetic fields (EMF) while permitting low frequency EMF through which
stabilize the cell by polarization. Farabloc has been successfully used by
many people in dealing with conditions causing chronic pain, e.g.
osteoarthritis, carpal tunnel syndrome and reflex sympathetic disorder.
Dr. Bach collected data for 4 years, in two phases, the first with
126 patients and the second, 24. All were hospitalized for 21 days. Each
patient wore gowns made of Farabloc or non-active placebo fabric at night. The
results of those using Farabloc demonstrated a significant benefit, the
authors stated in Clinical Rheumatology.
"Patients with fibromyalgia had less pain after sleeping in a gown made
of Farabloc than with a placebo fabric. The changes from admission to
discharge were assessed in each group separately. Statistically significant
changes were shown in quantity of pain, quality of pain, and total paracetamol
use."
Dr. Clement, who would be available for interviews concerning the
fibromyalgia study and the history of Farabloc, stated in the past, "I have
been involved in sports medicine for many years, and I never came across a
product like Farabloc. This electromagnetic shielding fabric not only relieves
pain but also reduces inflammation. Farabloc is an effective drug free
alternative for pain reduction and injury recovery."
The current report in Clinical Rheumatology has been electronically
published on the journal's web site (www.springerlink.com). The medical report
is indexed by PubMed, the prestigious listing of research advances by the
United States National Library of Medicine of the National Institutes of
Health. This is the third article indexed by PubMed citing research studies of
Farabloc. The others concerned the effective use of Farabloc in treating
phantom limb pain and delayed-onset muscle soreness.
Frieder Kempe, president of Farabloc Development Corporation, began
experimenting with the Faraday Cage in 1983. He used the concepts of
19th century British scientist Michael Faraday, in the hope of helping his
father, an amputee deal with phantom limb pain. About the recent affirmation
04/02/2009 11:38 PM
CNW Telbec | FARABLOC DEVELOPMENT CORPORATION | Internat...
2 von 2
http://www.cnw.ca/fr/releases/archive/January2007/23/c8275.html
of his product's therapeutic impact, Kempe said: "It is satisfying in a
business sense and rewarding to see theories confirmed, but it is almost
overwhelming to think of how much relief this product has provided for so many
people."
For further information: Farabloc Development Corporation, Tel.
1-866-941-4711, E-mail: [email protected], Web site: www.farabloc.com
FARABLOC DEVELOPMENT CORPORATION - Renseignements sur cet organisme
Communiqués de presse Archives de photos CNW
(1)
>DITES-LE À UN AMI >VERSION IMPRIMABLE >ABONNEZ-VOUS À SENTINELLE CNW
© 2005 Groupe CNW Ltée
CONFIDENTIALITÉ ET MODALITÉS D’UTILISATION / AIDE / CARTE DU SITE
04/02/2009 11:38 PM